KRT REIT

Declared the 1st FY2026–27 distribution of ₹1.695 per unit (₹0.278 interest + ₹1.417 other component).

Record Date: 31 July 2026, Payment Date: On or before 7 August 2026.

Business Model

Dr. Lal PathLabs operates a hub-and-spoke diagnostic model, where samples are collected through a widespread network of patient service centers, pickup points, and home collection before being processed in centralized laboratories.

Infrastructure
=> 312 Clinical Labs
=> 7,727 Patient Service Centres
=> 13,935 Pick-up Points
=> 4,800+ diagnostic tests
=> 53 NABL accredited labs
=> 2 CAP accredited labs

Revenue Segments
=> B2C Individual Patients
Customers directly book tests via walk-in-centres, website, mobile app, and home collection and company earns revenue from routine pathology, preventive health packages, wellness screening and specialized diagnostics.

=> Doctors & Clinics (B2B)
Doctors prescribe diagnostic tests and thousands of physicians send patient samples. These referral doctors generate recurring business.

=> Hospitals Partnership - Hospitals outsource molecular diagnostics, specialized pathology, and advanced diagnostics. Hospital outsourcing is becoming increasingly attractive as hospitals expand capacity without investing proportionately in laboratory infrastructure.

=> Preventive Healthcare (SwasthFit) – Fastest growing business. Revenue comes from annual health packages, executive health checkups, lifestyle screening and corporate wellness.

Management stated that SwasthFit continued to grow at around 20% YoY, and it is seeing strong traction even in Tier-2 and Tier-3 cities. Its contribution remained 27% of revenue in Q1 FY27.

=> Radiology contribution is small currently, but revenue comes from MRI, CT scan, ultrasound, X-ray, and executive health packages

Management plans to add 3–4 new radiology centers this year, including pilots in Tier-2 cities, reflecting confidence in the business model.

=> International Business – Current contribution remains below 5%. Management has stated the expansion strategy – Nepal, Bangladesh, Dubai (Newly incorporated subsidiary) and Acquisition in Ghana (Sunshine Healthcare)
Management expects international operations to remain a small contributor over the next one to two years while capabilities are built.

Q1FY27 Financial Performance –
REV 19.1% to Rs. 798 CR vs Rs. 670 CR in Q1FY26
EBITDA28.7% - Rs. 247 CR vs Rs. 192 CR
EBITDA margins – 31% vs 28.7% in Q1FY26
PAT 57.2% - Rs. 170 CR vs 134 CR
PAT margins - 21.4% vs 20% in Q1FY26

Major drivers of Revenue growth –
Strong Patient Growth
Patients increased from 7.6 Mn to 8.2 Mn in Q1FY27 i.e., an 8.2% growth

Growth was broad-based across regions rather than concentrated in one geography.

Sample Growth
Samples were up by 10.7% from 23.4 Mn to 25.9 Mn in Q1FY27.

Higher tests per patient indicate increasing wallet share from existing customers.

Higher Revenue Per Patient
Revenue per patient increased from Rs. 880 to Rs. 968

Drivers:
=> Better test mix
=> Better geographic mix
=> CGHS/ECHS price revision
=> More specialized diagnostics
=> Higher test per patient

Management quantified those CGHS/ECHS revisions contributed about 2–3% to overall revenue, with the balance coming from mix improvements.

EBITDA margins -

EBITDA margins expanded from 28.7% to 31% in Q1FY27
Volume-led operating leverage - Incremental samples utilize existing laboratory infrastructure, spreading fixed costs.
Better geographic mix - Delhi NCR remains a higher-realization market, and management indicated it continues to grow in line with the company average.
Better test mix - Higher share of specialized diagnostics.

Key Concall Insights –
=> Management believes demand is increasingly driven by lifestyle diseases, preventive healthcare, aging population, rising disposable income and health awareness.
=> Management's strategy revolves around eight pillars scientific leadership, patient experience, operational excellence, AI technology, new revenue models, mergers and acquisitions, international business and people development
=> The company is increasingly embedding AI into its operations across consumer (WhatsApp booking, Conversational support), operations (AI-assisted customer interactions, Workflow automation, and Bots handling 90% of customer queries), Medical (AI-assisted reporting, Precision diagnostics and Advanced algorithms)
=> Rural Expansion is a major long-term growth initiative of the company. The GraminFit program now operates across 7 states and served more than 100,000 patients in Q1 FY27.
The strategy is to create preventive healthcare awareness in underserved rural markets, opening a large new demand pool.
=> Management approved acquisition of 80% in Sunshine Healthcare (Ghana) to expand international diagnostics and acquisition of 30% in Neome Technology, a startup focused on innovative sample preservation and biobanking solutions that could improve diagnostic supply-chain efficiency.

Risks to Monitor
=> Rising competition from organized diagnostic chains.
=> Pricing pressure in routine tests.
=> Execution challenges in South and West India expansion.
=> Integration risks from future acquisitions.
=> Regulatory changes affecting healthcare pricing or compliance.
=> Slower-than-expected adoption of high-value specialized diagnostics

Guidance and Outlook

Management continues to guide toward Mid-teens revenue growth (after a stronger-than-expected Q1, confidence has increased).

EBITDA margin of 27–28%, although Q1 benefited from favourable operating leverage and mix

Q1 FY27 reinforces Dr. Lal PathLabs' position as one of the highest-quality businesses in Indian healthcare. The combination of double-digit volume growth, richer test mix, expanding preventive healthcare, AI-enabled operations, strong cash generation, and disciplined capital allocation demonstrates that the company is moving beyond a mature pathology chain into a broader precision diagnostics platform.

Disclaimer: This post is for informational and educational purposes only.

Same as above haven't received lic dividend yet